Actionable insights straight to your inbox

Equities logo

Dr. Tina Sampalis M.D., Ph.D. Joins Relevium’s Board of Directors

Tina Sampalis, M.D., Ph.D., is an oncology surgeon trained in physiology at McGill University in Montreal, medicine at the University of Patras (Greece), dermatology at Göttingen University (Germany) and Marselisborg University (Denmark), pediatric, genera

Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”) a consolidator of e-commerce assets in Health and Wellness in conjunction with its board of directors, is pleased to announce the addition of Dr. Tina Sampalis to the Company’s Board of Directors.

Tina Sampalis, M.D., Ph.D., is an oncology surgeon trained in
physiology at McGill University in Montreal, medicine at the University
of Patras (Greece), dermatology at Göttingen University (Germany) and
Marselisborg University (Denmark), pediatric, general and oncology
surgery at the University of Athens (Greece), graduate training (Ph.D.)
in Surgical Research at the University of Athens and a second Ph.D. in
Epidemiology and Experimental Surgery at McGill University.

Dr. Sampalis’ leading work in Nutraceuticals includes Neptune Technologies & Bioressources,
where she discovered one of the primary reasons krill oil is so
beneficial to human health: Phospholipids. Dr. Sampalis is the named
inventor of Neptune’s composition and application patents. As the former
President of Acasti Pharma Inc.
she led the development of a novel patented active pharmaceutical
ingredient targeting the prevention and treatment of
hypertriglyceridemia and cardio metabolic-disorders.

She is the Founder and President of the AGOO Children’s Health & Wellness Center,
a state-of-the-art multidisciplinary comprehensive,
pediatric-adolescent medical center and accredited McGill University
teaching site in Quebec.

Dr. Sampalis has received several international scholarships
and awards for her work on the clinical implementation of retinols for
skin and breast cancer, including the Helen Hutchison Award for
geriatric medicine. Her work on scintimammography resulted in her
appointment at the International Educational Speakers Bureau, the
Canadian and U.S. Faculty of Medical Speakers for Breast Imaging.

As an international scholar, Dr. Sampalis leads the
development and implementation of innovative micro-invasive and
stereotactic robotic surgical techniques for breast cancer, for which a
U.S. and Canadian patent application has been filed. She is a member of
the American Association of Naturopathic Medicine. Dr. Sampalis has
published papers in multiple peer-reviewed publications. She was named
one of the 10 most successful women in Quebec (Les Affaires, 18-24
September 2010) and one of the 100 most successful globally by the
Princeton Global Network.

Relevium Technologies Inc. (TSX.V – “RLV”)
President and CEO, Aurelio Useche, stated, “We are very honored to have
Dr. Sampalis join our Company. The addition of Dr. Sampalis closes the
value chain by providing deep expertise in scientific and evidence based
nutraceutical and medical trends, which can be leveraged through the
consolidation of e-commerce assets such as BioGanix as announced on December 22, 2016.”

About Relevium Technologies Inc.

Relevium is a TSX Venture listed issuer focused on growth
through the acquisition of businesses, products and/or technologies with
a focus on e-commerce in the growing health and wellness sector,
specifically under three important verticals: Pain Relief, Recovery and
Performance. Relevium Technologies Inc. currently holds patented
intellectual property for application of static magnetic fields on
direct-to-consumer devices, which aid in decreasing pain, improving
recovery time and enhancing overall physical performance.

About BioGanix

BioGanix (
was founded with customer results in mind, to provide the best quality,
best researched, and most potent formulas at competitive prices, while
providing excellent and personal customer care. BioGanix puts our
customers first, and do everything we can to keep them happy.

BioGanix prides itself on using only the best and purest
ingredients in our manufacturing processes. BioGanix only provides
premium quality products, and doesn’t cut any corners in manufacturing
processes. All BioGanix products have been 3rd Party Laboratory tested
and verified, and are manufactured in GMP Certified and FDA inspected
facilities in the USA.

BioGanix currently has over 16 of the best-selling dietary supplement products available,
varying from trending weight loss products, to proven health supporting
supplements that supports various processes in the body, including
digestive health, heart health, brain health, blood sugar, as well as
anti-aging supplements.

Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this

Cautionary Note Regarding Forward-Looking Statements

This release includes certain statements and information that
may constitute forward-looking information within the meaning of
applicable Canadian securities laws or forward-looking statements within
the meaning of the United States Private Securities Litigation Reform
Act of 1995. All statements in this news release, other than statements
of historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future performance,
including the timing and completion of the proposed acquisitions, are
forward-looking statements and contain forward-looking information.
Generally, forward-looking statements and information can be identified
by the use of forward-looking terminology such as “intends” or
“anticipates”, or variations of such words and phrases or statements
that certain actions, events or results “may”, “could”, “should”,
“would” or “occur”. Forward-looking statements are based on certain
material assumptions and analysis made by the Company and the opinions
and estimates of management as of the date of this press release,
including the assumptions that the Company will obtain stock exchange
approval of the Offering, the proposed acquisition will occur as
anticipated, that the Company will raise sufficient funds, and that the
Company will obtain all requisite approvals of the acquisition. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level
of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information. Important
factors that may cause actual results to vary, include, without
limitation, the risk that the proposed acquisitions may not occur as
planned; the timing and receipt of requisite approvals and failure to
raise sufficient funds under the Offering. Although management of the
Company has attempted to identify important factors that could cause
actual results to differ materially from those contained in
forward-looking statements or forward-looking information, there may be
other factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove to
be accurate, as actual results and future events could differ materially
from those anticipated in such statements. Accordingly, readers should
not place undue reliance on forward-looking statements and
forward-looking information. Readers are cautioned that reliance on such
information may not be appropriate for other purposes. The Company does
not undertake to update any forward-looking statement, forward- looking
information or financial outlook that are incorporated by reference
herein, except in accordance with applicable securities laws. We seek
safe harbor.

On Behalf of the Board of Directors


Aurelio Useche, President and CEO

Contact Information

In the interest of full disclosure, we call the reader’s attention
to the fact that, Inc. is compensated by the companies
profiled in the Spotlight Companies section. The purpose of these
profiles is to provide awareness of these companies to investors in the
micro, small-cap and growth equity community and should not in any way
be considered as a recommendation to buy, sell or hold these securities. is not a registered broker dealer, investment advisor,
financial analyst, investment banker or other investment professional.
We are a publisher of original and third party news and information. All
profiles are based on information that is available to the public. The
information contained herein should not be considered to be complete and
is not guaranteed by to be free from misstatement or
errors. The views expressed are our own and not intended to be the basis
for any investment decision. Readers are reminded to do their own due
diligence when researching any companies mentioned on this website.
Always bear in mind that investing in early-stage companies is risky and
you are encouraged to only invest an amount that you can afford to lose
completely without any change in your lifestyle. Equities has been
compensated with cash, common shares and/or warrants for market
awareness services provided.

I’ve long said we are under-utilizing nuclear energy. This shouldn’t be controversial; nuclear has something for everyone.